Display options
Cite
Fukami K, Yamagishi S, Sakai K, et al. Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients. Clin Kidney J. 2014;7(5):470-4doi: 10.1093/ckj/sfu082.
Fukami, K., Yamagishi, S., Sakai, K., Nasu, M., & Okuda, S. (2014). Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients. Clinical kidney journal, 7(5), 470-4. https://doi.org/10.1093/ckj/sfu082
Fukami, Kei, et al. "Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients." Clinical kidney journal vol. 7,5 (2014): 470-4. doi: https://doi.org/10.1093/ckj/sfu082
Fukami K, Yamagishi S, Sakai K, Nasu M, Okuda S. Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients. Clin Kidney J. 2014 Oct;7(5):470-4. doi: 10.1093/ckj/sfu082. Epub 2014 Jul 29. PMID: 25878778; PMCID: PMC4379340.
Copy Download .nbib Format: NLM
Share it on

Clin Kidney J. 2014 Oct;7(5):470-4. doi: 10.1093/ckj/sfu082. Epub 2014 Jul 29.

Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients.

Clinical kidney journal

Kei Fukami, Sho-Ichi Yamagishi, Kazuko Sakai, Makoto Nasu, Seiya Okuda

Affiliations

  1. Division of Nephrology, Department of Medicine , Kurume University School of Medicine , Kurume , Japan.
  2. Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications , Kurume University School of Medicine , Kurume , Japan.

PMID: 25878778 PMCID: PMC4379340 DOI: 10.1093/ckj/sfu082

Abstract

BACKGROUND: Carnitine deficiency may contribute to cardiovascular disease (CVD) in patients with hemodialysis (HD). Dyslipidemia plays a role in CVD and its prevalence is also high in HD patients. We examined here the effects of switching from oral administration (PO) to intravenous (IV) injection of l-carnitine on lipid metabolism in patients with HD.

METHODS: Nine HD patients who had received l-carnitine orally (900 mg/day) for 1 year were enrolled in this study. We examined whether lipid parameters were improved by switching to IV injection therapy of 1000 mg l-carnitine.

RESULTS: IV injection of l-carnitine for 1 week significantly increased total, free and acyl carnitine levels both before and after HD. Switching to IV injection therapy for 1 and 4 weeks decreased serum free fatty acid (FFA) (322 ± 104 versus 261 ± 124 µmol/L) and increased high-density lipoprotein-cholesterol levels (1.46 ± 0.49 versus 1.63 ± 0.62 mmol/L), respectively. Change in FFA values from the baseline (ΔFFA) was positively correlated with the Δacyl/free carnitine ratio (r (2) = 0.553, P = 0.022).

CONCLUSION: This study demonstrated that switching to IV l-carnitine therapy from oral supplementation improved lipid profiles, thus supporting the clinical utility of IV administration of l-carnitine for the treatment of patients on HD.

Keywords: HDL-cholesterol; free fatty acid; hemodialysis; l-carnitine

References

  1. Pediatr Nephrol. 2012 Aug;27(8):1381-7 - PubMed
  2. Semin Dial. 2001 May-Jun;14(3):209-17 - PubMed
  3. Clin Biochem. 2004 Sep;37(9):785-90 - PubMed
  4. Lancet. 1978 Nov 25;2(8100):1160 - PubMed
  5. Rejuvenation Res. 2013 Dec;16(6):460-6 - PubMed
  6. J Am Soc Nephrol. 1997 Dec;8(12):1889-98 - PubMed
  7. Mediators Inflamm. 2007;2007:19891 - PubMed
  8. Am J Kidney Dis. 2003 Apr;41(4 Suppl 4):S13-26 - PubMed
  9. Nutr Clin Pract. 2005 Apr;20(2):218-43 - PubMed
  10. Rejuvenation Res. 2013 Jun;16(3):200-5 - PubMed
  11. Nephrol Dial Transplant. 2008 Jan;23(1):345-53 - PubMed
  12. Zhonghua Nei Ke Za Zhi. 2010 Jul;49(7):572-6 - PubMed
  13. Arch Med Res. 2003 Mar-Apr;34(2):89-99 - PubMed
  14. Nephrology (Carlton). 2012 Nov;17(8):689-94 - PubMed
  15. Nephrology (Carlton). 2011 Mar;16(3):299-303 - PubMed
  16. Nephrology (Carlton). 2010 Oct;15(7):692-9 - PubMed
  17. Clin Chem. 1994 May;40(5):817-21 - PubMed
  18. Clin Pharmacokinet. 2003;42(11):941-67 - PubMed
  19. Heart Vessels. 2014 Jan;29(1):35-41 - PubMed
  20. Clin Exp Pharmacol Physiol. 2008 Feb;35(2):168-73 - PubMed
  21. Jpn Heart J. 1982 May;23(3):349-59 - PubMed
  22. N Engl J Med. 2007 Sep 27;357(13):1301-10 - PubMed
  23. Tex Heart Inst J. 2013;40(1):104-5 - PubMed
  24. Saudi Med J. 2004 Nov;25(11):1611-6 - PubMed
  25. N Engl J Med. 1978 Dec 14;299(24):1326-9 - PubMed

Publication Types